Clinical trials articles from across Nature Portfolio

Despite rapid development of model algorithms, more evidence is needed on the widespread clinical implementation of auto-segmentation tools. In this prospective, multicenter, observational trial, the authors find that AI-assisted delineation performs better than manual delineation while improving time efficiency and reducing performance metrics variability across centers and physicians with varying expertise.

Patient recruitment remains a major bottleneck in clinical trials. Here, the authors present TrialMatchAI, an open-source AI-powered recommendation system that automates patient-to-trial matching from heterogeneous clinical data with state-of-the-art performance, high efficiency and interpretability, and secure local deployment.

In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.

Preclinical studies have evaluated murine double minue 2 (MDM2) inhibitors as a treatment for adenoid cystic carcinoma (ACC). Here the authors present a phase I clinical trial reporting tolerability and efficacy preliminary data for the MDM2 inhibitor alrizomadlin (APG-115) in patients with TP53 wild type salivary gland cancers, especially adenoid cystic carcinoma.

The small molecule rezatapopt binds a unique pocket in Y220C-mutant p53 and restores its tumor-suppressor function; a phase 1 study provides proof of concept of this therapeutic approach.

Although oncology advances stem from clinical research, <5% of global cancer trials actively recruit patients in Latin America. Herein, I discuss why expanding inclusive trial designs and fostering multisector partnerships are essential to reduce disparities and improve the role of Latin America in global oncology research. I present examples such as the recent regulatory reforms in Brazil that aim to accelerate study approvals, as well as collaborative initiatives between local and international research groups to further strengthen clinical trial capacity.

When used as intended, an AI stethoscope enhanced the detection of cardiovascular disease — but low uptake and workflow challenges hampered effectiveness in a large pragmatic trial.